ClinicalTrials.gov
ClinicalTrials.gov Menu

Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01347593
Recruitment Status : Completed
First Posted : May 4, 2011
Last Update Posted : January 17, 2013
Sponsor:
Collaborator:
Ministry of Health, Sudan
Information provided by (Responsible Party):
Ishag Adam, University of Khartoum

Brief Summary:
Ceftizoxime (Cefizox) will reduce post Cesarean delivery febrile morbidity.

Condition or disease Intervention/treatment Phase
Caesarean Drug: ceftizoxime Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery in Soba Hospital Sudan
Study Start Date : May 2011
Actual Primary Completion Date : August 2011
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cesarean Section

Arm Intervention/treatment
Experimental: ceftizoxime (cefizox) injection
ceftizoxime (cefizox) as single dose of 1 g at the interval of 30-60 minutes before the incision
Drug: ceftizoxime
ceftizoxime (cefizox) injection either after clamping the cord
Other Name: cefizox




Primary Outcome Measures :
  1. reducing post Cesarean section febrile morbidity [ Time Frame: 4 days ]
    reducing infection rate



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Elective Cesarean section

Exclusion Criteria:

  • Diabetes severe anaemia allergy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01347593


Locations
Sudan
Soba Hospital
Khartoum, Sudan, 249
Sponsors and Collaborators
University of Khartoum
Ministry of Health, Sudan

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ishag Adam, Professor, University of Khartoum
ClinicalTrials.gov Identifier: NCT01347593     History of Changes
Other Study ID Numbers: ceftizoxime cesarean
First Posted: May 4, 2011    Key Record Dates
Last Update Posted: January 17, 2013
Last Verified: January 2013

Keywords provided by Ishag Adam, University of Khartoum:
ceftizoxime
Cesarean
post caesarean febrile morbidity

Additional relevant MeSH terms:
Ceftizoxime
Anti-Bacterial Agents
Anti-Infective Agents